Immuno Oncology target disease positioning using multi-omic analysis

• Research type

  Research Study

• Full title

  Immuno Oncology target disease positioning using multi-omic analysis

• IRAS ID

  312047

• Contact name

  Gayle Marshall

• Contact email

  gayle.marshall@md.catapult.org.uk

• Sponsor organisation

  Lifearc

• Duration of Study in the UK

  1 years, 9 months, 29 days

• Research summary

  Medicines Discovery Catapult (MDC) are investigating the expression of various oncology targets/biomarkers within a wide variety of oncology samples, with a view to developing a patient selection approach for more effective treatment of these cancers.

  MDC are looking to access human oncology sample tissue microarrays (TMA) through commercially available biobanks from various tissue origins including melanoma, head and neck squamous cell carcinoma (HNSCC), colorectal carcinoma (CRC) and others. This work will involve transcriptomic, proteomic, metabolomic and lipidomic analysis using a variety of technology platforms including the Nanostring GeoMx, histology, microscopy and mass spectrometry imaging, to determine expression levels and distribution of immune oncology targets of interest. Selected samples will also be shipped to collaborators at University of Leicester for immunofluorescence and IHC analysis.

• REC name

  HSC REC A

• REC reference

  22/NI/0069

• Date of REC Opinion

  24 May 2022

• REC opinion

  Further Information Favourable Opinion